- Home
- LZM vs EIKN Comparison
LZM vs EIKN Comparison
Compare LZM & EIKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LZM | EIKN |
|---|---|---|
| Founded | 2021 | 2019 |
| Country | Isle of Man | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 336.3M | 316.3M |
| IPO Year | 2023 | 2026 |
Fundamental Metrics
Financial Performance| Metric | LZM | EIKN |
|---|---|---|
| Price | $4.11 | $5.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $8.63 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 576.1K | 535.4K |
| Earning Date | 07-29-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $182.86 | N/A |
| Revenue Next Year | $16.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.95 | $5.01 |
| 52 Week High | $6.40 | $16.50 |
Technical Indicators
Market Signals| Indicator | LZM | EIKN |
|---|---|---|
| Relative Strength Index (RSI) | 57.95 | 41.94 |
| Support Level | $3.79 | $5.01 |
| Resistance Level | $4.17 | $8.48 |
| Average True Range (ATR) | 0.35 | 0.60 |
| MACD | 0.08 | 0.11 |
| Stochastic Oscillator | 67.97 | 49.24 |
Price Performance
Historical ComparisonAbout LZM Lifezone Metals Limited
Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania, and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate. Geographically, the company operates in South Africa, Australia, and the rest of the world. The majority of its revenue is generated from Australia.
About EIKN Eikon Therapeutics Inc. Common Stock
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.